International Development Grant
Global Fund to Fight AIDS Tuberculosis and Malaria - COVID-19 Response Phase II
Project Number: CA-3-P010788001
Status: Operational
Country/Region: Unknown
Regional Focus:
Maximum Contribution: $160,000,000.00
Start Date: December 23, 2021
End Date: December 31, 2026
Duration: 5.0 years
Project Description
This project supports countries to respond to the COVID-19 pandemic and to mitigate the impact of COVID-19 on programs to fight Human Immunodeficiency Virus or Acquired Immunodeficiency Syndrome (HIV or AIDS) tuberculosis and malaria. The project also supports countries to recover from COVID-19 through strengthening health systems and future pandemic preparedness and response. Project activities include: (1) procuring and delivering approximately 6 329 000 antigen rapid diagnostic tests to low-income and lower middle-income countries. The most severely-affected countries in Africa are expected to benefit from 75% of the supplies and 25% would go to the hardest-hit countries in Asia; (2) supporting new approaches to continue access to HIV tuberculosis and malaria services during the pandemic. These include virtual health service delivery door-to-door delivery of mosquito nets and dual COVID-19 and tuberculosis screening programs; and (3) supporting gender-based violence prevention and post-violence care programs in the context of increased gender and intimate partner violence during COVID-19 lockdowns.
Expected Results
The expected outcomes for this project include: (1) increased support provided for country responses to the pandemic; (2) impact of COVID-19 on the fight against HIV tuberculosis and malaria mitigated; and (3) improved health and community systems.
Progress & Results Achieved
Results achieved through the support of Canada and other international donors as of April 2023 include: (1) the COVID-19 Response Mechanism (C19RM) enabled a steady and reliable supply and delivery of COVID-19 diagnostic tests and Personal Protective Equipment (PPE) materials enabling countries to acquire urgently needed commodities in advance of the peak of the Omicron variant in 2022. Cumulatively the project facilitated the delivery of 66.3 million Antigen Rapid Diagnostic Tests and 15.5 million Polymerase Chain Reaction (PCR) tests to countries; (2) due to its market shaping capacity as a major procurer and supplier of health commodities worldwide Global Fund interventions helped bring down the price of Antigen Rapid Diagnostics Tests from over US$5 per unit to US$1 rendering diagnostics more affordable to low and middle-income countries; (3) through programs supported by the C19RM tuberculosis programs rebounded strongly in 2022 with the majority of countries having reached pre-COVID levels of tuberculosis case reporting by the end of 2022; and (4) The C19RM supported countries to adopt innovative interventions to maintain and improve health service provision. For example the C19RM supported countries to roll-out bidirectional testing enabling patients to be simultaneously screened and tested for Tuberculosis and COVID-19. This enabled the onward transmission of both diseases to be halted and helped to ensure the diagnoses treatment and cure of people with both diseases.
Key Information
Executing Agency:
Global Fund to Fight AIDS Tuberculosis & Malaria
Reporting Organization:
Global Affairs Canada
Program:
YFMInternaAssistPartnershp&Programing Br
Last Modified:
September 19, 2025
Development Classifications
DAC Sector:
Aid Type: Contributions to multi-donor/single-entity funding mechanisms
Collaboration: Bilateral
Finance Type: Aid grant excluding debt reorganisation
Selection Mechanism:
Department-Initiated